DDInter1938 DDInter1174
Vincristine is a vinca alkaloid with formula C46H56N4O10 found in the Madagascar periwinkle, Catharanthus roseus. It is used (commonly as the corresponding sulfate salt)as a chemotherapy drug for the treatment of leukaemia, lymphoma, myeloma, breast cancer and head and neck cancer. It has a role as a tubulin modulator, a microtubule-destabilising agent, a plant metabolite, an antineoplastic agent and a drug. It is a methyl ester, an acetate ester, a tertiary alcohol, a member of formamides, an organic heteropentacyclic compound, an organic heterotetracyclic compound, a tertiary amino compound and a vinca alkaloid. It is a conjugate base of a vincristine(2+). It derives from a hydride of a vincaleukoblastine.
Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma.[A180322,L7144,L7147,L7150,L7180] Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients are intolerant of those treatments. Methotrexate was granted FDA approval on 7 December 1953.
Vincristine {u} (Compound) treats {v} (Disease) lymphatic system cancer
lymphatic system cancer {u} (Disease) is treated by {v} (Compound) Methotrexate
Vincristine {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Methotrexate
Vincristine {u} (Compound) downregulates {v} (Gene) TYMS
TYMS {u} (Gene) is bound by {v} (Compound) Methotrexate
Vincristine {u} (Compound) downregulates {v} (Gene) TIMELESS
TIMELESS {u} (Gene) is upregulated by {v} (Compound) Methotrexate
Vincristine {u} (Compound) upregulates {v} (Gene) RELB
RELB {u} (Gene) is upregulated by {v} (Compound) Methotrexate
Vincristine {u} (Compound) upregulates {v} (Gene) AGO2
AGO2 {u} (Gene) is downregulated by {v} (Compound) Methotrexate
Vincristine {u} (Compound) downregulates {v} (Gene) CDC25B
CDC25B {u} (Gene) is downregulated by {v} (Compound) Methotrexate
Vincristine {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Methotrexate
Vincristine {u} (Compound) resembles {v} (Compound) Vinblastine
Vinblastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methotrexate
Vincristine {u} (Compound) resembles {v} (Compound) Vinorelbine
Vinorelbine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methotrexate
Vincristine (Compound) treats lymphatic system cancer (Disease) and lymphatic system cancer (Disease) is treated by Methotrexate (Compound)
Vincristine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Methotrexate (Compound)
Vincristine (Compound) downregulates TYMS (Gene) and TYMS (Gene) is bound by Methotrexate (Compound)
Vincristine (Compound) downregulates TIMELESS (Gene) and TIMELESS (Gene) is upregulated by Methotrexate (Compound)
Vincristine (Compound) upregulates RELB (Gene) and RELB (Gene) is upregulated by Methotrexate (Compound)
Vincristine (Compound) upregulates AGO2 (Gene) and AGO2 (Gene) is downregulated by Methotrexate (Compound)
Vincristine (Compound) downregulates CDC25B (Gene) and CDC25B (Gene) is downregulated by Methotrexate (Compound)
Vincristine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Methotrexate (Compound)
Vincristine (Compound) resembles Vinblastine (Compound) and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate
Vincristine (Compound) resembles Vinorelbine (Compound) and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate